Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRV NASDAQ:EDSA NASDAQ:OTLK NASDAQ:XCUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRVAcrivon Therapeutics$1.51-3.8%$1.70$1.15▼$3.56$64.63M1.891.30 million shs294,646 shsEDSAEdesa Biotech$6.86+0.4%$9.19$0.72▼$20.32$60.99M1.032.81 million shs148,623 shsOTLKOncobiologics$0.81-0.5%$0.30$0.16▼$3.39$113.41M0.9610.91 million shs10.48 million shsXCURExicure$3.08-1.0%$3.61$2.63▼$10.80$19.62M3.5325,324 shs2,691 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRVAcrivon Therapeutics+0.64%-5.99%-24.88%-7.10%+41.44%EDSAEdesa Biotech+2.09%-29.59%-61.17%+59.95%+243.22%OTLKOncobiologics-3.49%+103.30%+210.30%+85.54%-54.03%XCURExicure-6.61%+16.48%-4.31%-12.89%-70.27%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRVAcrivon Therapeutics$1.51-3.8%$1.70$1.15▼$3.56$64.63M1.891.30 million shs294,646 shsEDSAEdesa Biotech$6.86+0.4%$9.19$0.72▼$20.32$60.99M1.032.81 million shs148,623 shsOTLKOncobiologics$0.81-0.5%$0.30$0.16▼$3.39$113.41M0.9610.91 million shs10.48 million shsXCURExicure$3.08-1.0%$3.61$2.63▼$10.80$19.62M3.5325,324 shs2,691 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRVAcrivon Therapeutics+0.64%-5.99%-24.88%-7.10%+41.44%EDSAEdesa Biotech+2.09%-29.59%-61.17%+59.95%+243.22%OTLKOncobiologics-3.49%+103.30%+210.30%+85.54%-54.03%XCURExicure-6.61%+16.48%-4.31%-12.89%-70.27%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRVAcrivon Therapeutics 2.60Moderate Buy$11.67672.63% UpsideEDSAEdesa Biotech 2.00Hold$5.00-27.11% DownsideOTLKOncobiologics 2.00Hold$4.50455.69% UpsideXCURExicure 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest XCUR, ACRV, EDSA, and OTLK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026ACRVAcrivon Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/28/2026XCURExicure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/18/2026OTLKOncobiologics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral5/14/2026ACRVAcrivon Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/27/2026ACRVAcrivon Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)3/27/2026EDSAEdesa Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026OTLKOncobiologics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/11/2026OTLKOncobiologics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $6.00(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRVAcrivon TherapeuticsN/AN/AN/AN/A$3.57 per shareN/AEDSAEdesa BiotechN/AN/AN/AN/A$0.45 per shareN/AOTLKOncobiologics$1.35M84.01N/AN/A($0.60) per share-1.35XCURExicure$500K39.24N/AN/A$0.62 per share4.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRVAcrivon Therapeutics-$77.90M-$2.00N/AN/AN/AN/A-64.43%-57.08%8/12/2026 (Estimated)EDSAEdesa Biotech-$7.19M-$1.34N/AN/AN/AN/A-286.52%-75.36%8/14/2026 (Estimated)OTLKOncobiologics-$62.42M-$1.17N/AN/AN/AN/AN/A-291.28%8/13/2026 (Estimated)XCURExicure-$4.95M-$1.55N/AN/AN/AN/A-179.41%-64.37%8/7/2026 (Estimated)Latest XCUR, ACRV, EDSA, and OTLK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2026Q1 2026XCURExicure-$18.60-$0.29+$18.31-$0.29$1.64 millionN/A5/15/2026Q2 2026OTLKOncobiologics-$0.12-$0.16-$0.04-$0.05$4.39 million$0.13 million5/14/2026Q2 2026EDSAEdesa Biotech-$0.24-$0.49-$0.25-$0.49$0.05 millionN/A5/13/2026Q1 2026ACRVAcrivon Therapeutics-$0.49-$0.49N/A-$0.49$0.28 millionN/A3/25/2026Q4 2025XCURExicure-$18.60-$0.46+$18.14-$0.46$1.64 millionN/A3/19/2026Q4 2025ACRVAcrivon Therapeutics-$0.49-$0.49N/A-$0.49$0.17 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACRVAcrivon TherapeuticsN/AN/AN/AN/AN/AEDSAEdesa BiotechN/AN/AN/AN/AN/AOTLKOncobiologicsN/AN/AN/AN/AN/AXCURExicureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRVAcrivon TherapeuticsN/A8.988.98EDSAEdesa BiotechN/A4.764.76OTLKOncobiologicsN/A0.540.45XCURExicureN/A0.791.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRVAcrivon Therapeutics71.62%EDSAEdesa Biotech5.50%OTLKOncobiologics11.20%XCURExicure42.82%Insider OwnershipCompanyInsider OwnershipACRVAcrivon Therapeutics8.50%EDSAEdesa Biotech24.40%OTLKOncobiologics2.80%XCURExicure52.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRVAcrivon Therapeutics5842.80 million39.16 millionNot OptionableEDSAEdesa Biotech208.89 million6.72 millionNot OptionableOTLKOncobiologics20140.05 million117.48 millionOptionableXCURExicure506.37 million3.01 millionNot OptionableXCUR, ACRV, EDSA, and OTLK HeadlinesRecent News About These CompaniesExicure Regains Nasdaq Compliance After Late Quarterly FilingJune 1 at 4:11 PM | tipranks.comExicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-QJune 1 at 4:00 PM | globenewswire.comExicure (NASDAQ:XCUR) Shares Up 4.5% - Here's What HappenedMay 28, 2026 | americanbankingnews.comExicure delays quarterly filing, trims quarterly lossMay 15, 2026 | tipranks.comExicure, Inc. and Adbiotech Co., Ltd. Announce Co-Development Agreement for Burixafor Combination TherapiesApril 22, 2026 | quiverquant.comQExicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)April 22, 2026 | globenewswire.comExicure Inc.April 13, 2026 | barrons.comExicure Strengthens Leadership With New COO and DirectorApril 10, 2026 | tipranks.comSummary Notice of Pendency and Proposed Settlement of Stockholder Derivative ActionsApril 2, 2026 | globenewswire.comExicure, Inc. Reports 2025 Financial Results and Announces Need for Additional FinancingMarch 25, 2026 | quiverquant.comQExicure, Inc. Reports 2025 Financial Results and Highlights Need for Additional FinancingMarch 25, 2026 | quiverquant.comQExicure, Inc. Reports Full Year 2025 Financial ResultsMarch 25, 2026 | globenewswire.comExicure, Inc. Reports Full Year 2025 Financial ResultsMarch 25, 2026 | globenewswire.comExicure, Inc. Publishes Phase 2 Study Results for Burixafor, a Novel CXCR4 Inhibitor in Hematologic Disease TreatmentFebruary 5, 2026 | quiverquant.comQExicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing TransplantFebruary 5, 2026 | globenewswire.comExicure, Inc. to Present Phase 2 Trial Results for Burixafor at 2026 ASTCT and CIBMTR Tandem MeetingsJanuary 21, 2026 | quiverquant.comQExicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem MeetingsJanuary 21, 2026 | globenewswire.comSangsangin Investment & Securi Sells 433,332 Shares of Exicure (NASDAQ:XCUR) StockDecember 11, 2025 | insidertrades.comFutures tread cautiously pre-market as investors await key Fed decision: NVDA, XCUR, GME, CASY among stocks to watchDecember 10, 2025 | msn.comThis BlackRock stock just rocketed 70%December 9, 2025 | finbold.comFNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXCUR, ACRV, EDSA, and OTLK Company DescriptionsAcrivon Therapeutics NASDAQ:ACRV$1.51 -0.06 (-3.82%) Closing price 04:00 PM EasternExtended Trading$1.53 +0.02 (+1.13%) As of 05:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.Edesa Biotech NASDAQ:EDSA$6.86 +0.03 (+0.44%) Closing price 04:00 PM EasternExtended Trading$7.08 +0.22 (+3.18%) As of 05:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.Oncobiologics NASDAQ:OTLK$0.81 0.00 (-0.47%) Closing price 04:00 PM EasternExtended Trading$0.79 -0.02 (-2.32%) As of 05:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.Exicure NASDAQ:XCUR$3.08 -0.03 (-0.96%) Closing price 03:58 PM EasternExtended Trading$3.08 +0.00 (+0.16%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palo Alto Networks Accelerates Growth 31% on AI Demand Motorola's $1.5B Bet to Own the Skies Microsoft Build 2026 Is Really Just One Big AI Stress Test Slice of the Pie: Why Yum’s Deal Lifts QSR Urban Outfitters Stock Stalls Despite Another Strong Quarter What IBM's $10-Billion Quantum Project Means For Smaller Players Marvell Stock Soars on NVIDIA's Trillion-Dollar Nod HIVE Earnings Highlight AI Ambitions Beyond Bitcoin Mining Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
